A Study to Evaluate the Impact on Skin (Injection Site) Reactions of Using Alcohol Wipes Prior to Daily Injections of Copaxone®.
NCT ID: NCT00220922
Last Updated: 2011-04-08
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE4
50 participants
INTERVENTIONAL
2004-08-31
2006-02-28
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Study to Evaluate the Impact of Using Warm Compress Prior to Daily Injections of Copaxone®
NCT00239993
A Study to Evaluate Readiness to Self-inject on Adherence and Compliance to Copaxone® Therapy
NCT00238654
Copaxone Subcutaneous Injection Syringe Special Drug Use-Result Investigation (All-Case Investigation) "Prevention of Relapse of Multiple Sclerosis"
NCT03209479
Safety and Efficacy Study of Copaxone Administered in Combination With N-Acetylcysteine
NCT00203099
Herbal Therapy for Subcutaneous Injection Site Reactions in Multiple Sclerosis
NCT00972062
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
CROSSOVER
PREVENTION
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
1
injection site reactions with the use of alcohol wipes prior to performing the patients' daily Copaxone® injection
Alcohol Wipes vs. No Alcohol Wipes
2
injection site reactions without the use of alcohol wipes prior to performing the patients' daily Copaxone® injection
Alcohol Wipes vs. No Alcohol Wipes
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Alcohol Wipes vs. No Alcohol Wipes
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* 18 years of age or older
* Diagnosis of RRMS
* Beginning or recently (within 3 months) began self-injecting Copaxone® subcutaneously
Exclusion Criteria
* Pregnant, or trying to become pregnant, or breast feeding during the study
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Teva Neuroscience, Inc.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Teva Neuroscience
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
MerriKay Oleen-Burkey, Ph.D.
Role: STUDY_DIRECTOR
Teva Neuroscience, Inc.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
PM013
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.